Chen Z
Jiangsu Institute of Hematology, First Affiliated Hospital, Suzhou University, China.
Int J Hematol. 2001 Jan;73(1):39-46. doi: 10.1007/BF02981901.
WT1, a tumor suppressor gene responsible for the development of childhood kidney tumors, is now also thought to be involved in the occurrence of human leukemia. First, evidence has shown that WT1 functions during hematopoiesis and regulates the proliferation and differentiation of blood cells. Second, specific expression patterns of this gene correlate with the malignant phenotype of leukemia compared with the physiological situation. Third, mutations of WT1 can be detected, though not frequently, in human leukemia but not in normal hematopoietic cells. Thus, a possible role of WT1 in human leukemogenesis has been proposed. Because the expression of this gene is relatively high during the so-called myelodysplastic stages and in all subtypes of human leukemia compared with normal blood cells, the notion has been raised that WT1 can be used as a "panleukemic marker" for the diagnosis of leukemia at the molecular level. The expression level of WT1 may have significance in predicting prognosis and monitoring relapse. Moreover, with a deeper understanding of its role in leukemogenesis, WT1 may serve as a target molecule in the strategy of gene therapy for leukemia.
WT1是一种与儿童肾肿瘤发生相关的肿瘤抑制基因,现在也被认为与人类白血病的发生有关。首先,有证据表明WT1在造血过程中发挥作用,并调节血细胞的增殖和分化。其次,与生理情况相比,该基因的特定表达模式与白血病的恶性表型相关。第三,虽然在人类白血病中可以检测到WT1的突变,但频率不高,而在正常造血细胞中则检测不到。因此,有人提出WT1在人类白血病发生过程中可能发挥作用。由于与正常血细胞相比,该基因在所谓的骨髓发育异常阶段以及人类白血病的所有亚型中表达相对较高,因此有人提出WT1可作为分子水平诊断白血病的“全白血病标志物”。WT1的表达水平在预测预后和监测复发方面可能具有重要意义。此外,随着对其在白血病发生中作用的深入了解,WT1可能成为白血病基因治疗策略中的一个靶分子。